Systemic Lupus Erythematous SLE Drugs Market

ethansmith

Systemic Lupus

Erythematous SLE

Drugs Market

Share, Global Trends,

Analysis, Research, Report,

Opportunities,

Segmentation and Forecast,

2015

Future Market Insights

www.futuremarketinsights.com

sales@futuremarketinsights.com


Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting

services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,

technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.

We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.

Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and

Retail.

We have a global presence with delivery centers across India specializing in providing global research reports and country

research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.

We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for

our client.

Research Capabilities

• Customized Research

• Syndicated Research

• Investment Research

• Social Media Research

Sector Coverage

• Automotive and Transportation

• Electronics, Semiconductor, and ICT

• Retail and Consumer Products

• Industrial Automation and Equipment

• Chemicals & Materials

• Food and Beverages

• Services and Utilities

• Energy, Mining, Oil, and Gas

Customized

Research

Syndicated

Research

Investment

Research

Social Media

Research

Subscription Information

For detailed subscription information please contact

Hari. T (Sr. Manager - Global Business Development)

T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268

Email: hari.t@futuremarketinsights.com


Report Description

Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease which causes the

immune system to mistakenly attack health body tissue. In SLE, body immune system can

affect any part of the body, such as joints, organs, eyes, skin, etc. Often SLE can result in

symptoms such as malar rash, discoid lesions, sub-acute cutaneous lesions,

photosensitivity, oral ulcers, arthritis, serositis, nephropathy, neurologic involvement,

thrombocytopenia, haemolytic anemia, fever, Raynaud’s phenomenon, livedo reticularis,

thrombosis, and myositis. It is also known as a disease of flare-ups and remissions and

can range from mild to life threatening severity. It is also called as drug-induced lupus

erythematosus due to common observation against drugs such as isoniazid, hydralazine

and procainamide. Currently, there is no complete treatment for SLE. While only two

biologic agents have been approved by FDA to treat SLE, synthetic drugs are still the

mainstay of therapy in SLE. Based on available evidence, azathioprine and

mycophenolate mofetil are the drugs of first choice. Hydroxychloroquine should be

considered an anchor drug in SLE because of the multiple beneficial effects of this agent.

Browse Full Report@ http://www.futuremarketinsights.com/reports/systemic-lupuserythematous-sle-drugs-market

Systemic Lupus Erythematous (SLE) Drugs Market: Drivers & Restraints

Global Systemic Lupus Erythematous (SLE) Drugs market is projected to grow due to high

prevalence of autoimmune diseases particularly systemic lupus erythematous (SLE).

Major drivers for global systemic erythematous drugs market are development of novel

SLE therapies, increasing availability of bio similar drugs and increasing support for


Report Description

At the same time, increasing awareness of disease diagnosis and treatment as well as

consistent research and development processes for novel drug molecules are important

drivers for global lupus erythematous market. Additionally, safety and quality of systemic

lupus erythematous controlling therapy may possibly be a challenge for the growth of the

global systemic lupus erythematous drugs market. Moreover, numerous public awareness

programs targeted to increase awareness levels are also being accompanied. For

instance, Lupus Foundation of America (LFA) has been implementing various projects to

increase central support for SLE research and services to support people and families

affected by SLE. However, serious side effectswith steroids, sensitivity with antibiotics,

limited usage of Benlysta for severe SLE patients, and stringent regulatory approvals for

new treatment options with better levels of efficacy and safety are obstructing the global

systemic lupus erythematous drugs market.

Systemic Lupus Erythematous (SLE) Drugs Market: Segmentation

The global systemic lupus erythematous drugs market is classified on the basis of

molecule and region.

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1149

Based on type of molecule, the global systemic lupus erythematous drugs market is

segmented into the following:

Corticosteroids

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)


Report Description

Anti-Inflammatories

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Antimalarials

BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)

Immunosuppressive Agents/Immune Modulators

Anticoagulants

Systemic Lupus Erythematous (SLE) Drugs Market: Overview

Global systemic lupus erythematous drugs market growth is fast in North American

region and is estimated to project remarkable CAGR growth throughout forecast period.

In North America, the SLE is more prevalent among Hispanics, Asians, and Native

Americans according to Centers for Disease Control and Prevention (CDC). The second

largest and fastest growing global systemic lupus erythematous drugs market is Europe

and is projected to reach nearly US$ 550 Mn and register a double digit CAGR due to

higher prevalence of SLE in Europe. Among the European countries Sweden, Iceland,

Spain had the highest prevalence according to Lupus Journal article, published in 2006. A

drug called hydroxychloroquine being the last drug was approved by FDA in 1955 for SLE

treatment. Recently, a drug called belimumab has been approved by FDA after 50 years

long gap specifically for SLE on March 9, 2011. It is the first ever targeted biological drug

for the treatment of SLE patients developed by Human Genome Sciences Inc.


Report Description

Benlysta will lead market sales in coming years because of its excellent safety profile as

well as proven efficacy in clinical trials. NSAIDS such as Ibuprofen and aspirin are widely

prescribed drugs for suppressing symptoms of SLE. Immunosuppressants by Roche

(CellCept (Mycophenolate mofetil), by Novartis (Neoral (Cyclosporine)), by GSK (Imuran

(Azathioprine)) are also commonly prescribed for SLE treatment. Additionally, the entry

of four first-in-class (FIC) biologics such as Bristol-Myers Squibb’s Orencia (abatacept),

atacicept, epratuzumab and LY2127399 are anticipated to show a major role in the

expansion of the global systemic lupus erythematous drugs market.

Request Free Report Sample@

http://www.futuremarketinsights.com/reports/sample/rep-gb-1149

Systemic Lupus Erythematous (SLE) Drugs Market: Key Players

The global systemic lupus erythematous drugs market key players are Anthera

Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS,

Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical

Industries.


Thank You!

To know more about us, please visit our website:

www.futuremarketinsights.com

For sales queries or new topics email us on:

sales@futuremarketinsights.com

For other queries contact: Mr. Sudip Saha

Future Market Insights: 616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989, United States

T: +1-347-918-3531 | D: +1-845-579-5705

More magazines by this user
Similar magazines